S1262
Clinical - Urology
ESTRO 2026
clinicopathological features and ADT duration are shown in Table 2. On multivariable logistic regression, only PSA (OR=1.17, p<0.001) and T stage >T2c (OR=14.0, p<0.001) independently associated with extended duration of ADT (more than 6 months). Median follow-up 57 months (range 5.6– 73.2). Median bPFS and OS were not reached for the whole cohort. Means of bPFS and OS based on the duration of ADT were compared.Patients with the high-risk features (PSA ≥ 20ng/mL and/or >T2c disease; n=204), showed mean bPFS of 69.8months for those who received 6-months of ADT (80/204) compared to 70.9months for extended ADT (124/204) (p=0.61), while mean OS was 70.3 and 70.5months(p=0.55) in the 6-month and the extended ADT cohorts respectively.Within the 6-month cohort, GG2 patients with high-risk features had a mean bPFS of 70.4m compared to 72.1m in those without high-risk features(p=0.30). Mean OS was 71.1m and 70.5m(p=0.43) for patients with high-risk features compared to the no high-risk feature cohort. In GG3 patients, bPFS was 68.6m compared to 71.4m(p=0.11) and mean OS 68.8m compared to 71.5m (p=0.10) for those with and without high-risk features, respectively.In the extended ADT cohort, GG2 patients' mean OS was 69.6m compared to 71.4m(p=0.80), while in GG3 patients, mean OS was 70.9m compared to 63.4m(p=0.63) for those with high and standard risk features accordingly. No biochemical failures recorded in this cohort. Conclusion: Extended ADT did not improve the outcomes in intermediate-risk Pca with high-risk features. These findings flag the unmet clinical need for prospective validation of integration of template biopsy findings into the clinical decision.
affected 17.6% (3/17 evaluable), 2 were relieved at last FU. In univariate analysis IPSS score was not correlated with acute toxicity (r=0.16; p=0.426) but with late toxicity (r=0.64; p=0.006); PTV was correlated with late and acute toxicity (r=0.672; p=0.003 and r=0.46; p=0.018, respectively). Conclusion: In prostate SBRT, PTV boost emerges as the dominant independent predictor of late GU toxicity (r=0.660, p=0.003), with IPSS providing additive prognostic value (r=0.64; p=0.006) for patient selection. These findings align with broader SBRT literature, emphasizing the need of dosimetric and clinical constraints to minimize urinary morbidity while preserving efficacy. Keywords: prostate, SBRT, toxicity Patterns and outcomes of androgen deprivation therapy duration in intermediate-risk prostate cancer Nashwah Ismail 1 , Libby Baines 2 , Ananya Choudhury 1,3 , Ereny Samwel Poles Saad 1 1 Clinical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom. 2 Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom. 3 Division of Cancer Sciences, The University of Manchester, Manchester, United Kingdom Digital Poster 3406 Purpose/Objective: Six months of androgen deprivation therapy (ADT) with radiotherapy (RT) is a standard approach for intermediate-risk prostate cancer (PCa) as per NICE/EAU guidelines, yet planned ADT duration remains heterogeneous. This study examined real- world determinants of ADT duration and impacts on outcomes. Material/Methods: Patients with intermediate-risk PCa treated with ADT from 2019-2021 were reviewed. Clinical data included demographics, histopathology, TNM, PSA and outcomes. Patients stratified according to Gleason Grade Group (GG) classification into GG2 and GG3, corresponding to favourable and unfavourable intermediate-risk. ADT duration classified as 6 months or >6 months. Associations between ADT duration and clinicopathological variables analysed using Pearson’s coefficients. Biochemical recurrence defined as PSA nadir + 2ng/mL. Biochemical progression-free survival (bPFS) and overall survival (OS) were estimated by Kaplan–Meier analyses and compared with log-rank tests. Results: 520 patients were included. Baseline characteristics summarised in Table 1. Associations of
Made with FlippingBook - Share PDF online